* NOVARTIS DATA CONFIRM RAPID RESPONSE AND HIGH EFFICACY OF COSENTYX® IN PSORIASIS PATIENTS FOR FIRST TIME IN CHINA
* PHASE III STUDY SHOWS CLOSE TO 9/10 PATIENTS WHO RECEIVED COSENTYX® 300MG ACHIEVED CLEAR OR ALMOST CLEAR SKIN DURING FIRST 16 WEEKS OF TREATMENT (87%), WITH RAPID ONSET OF RELIEF SEEN AS EARLY AS WEEK 3
* RESULTS STRENGTHEN UNIQUE POSITION OF COSENTYX AS A RAPID AND LONG-LASTING COMPLETE TREATMENT OF PSORIATIC DISEASE, WITH OVER 200,000 PATIENTS TREATED WORLDWIDE
* DATA IS BEING PRESENTED AT 2019 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING IN WASHINGTON, D.C Source text for Eikon
